Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07094204 · ClinicalTrials.gov registry record · Phase 1
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
A Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, sponsored by Astellas Pharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 364
- Enrollment target
- 12
- Study locations
NCT07094204 is a Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer that is actively recruiting participants, run by Astellas Pharma. The registered enrollment target is 364 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (45% lower). The trial reports 12 study locations across 10 states.
The verdict
NCT07094204, a Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, is actively recruiting participants, sponsored by Astellas Pharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 364 participants
- Enrollment target
- 12
- Study locations
Study Summary
Genes contain genetic code which tell the body which proteins to make. Many types of cancer are caused by changes, or mutations, in a gene called KRAS. Researchers are looking for ways to stop the actions of abnormal proteins made from the mutated KRAS gene. ASP5834 is being studied in people with solid tumors who have certain KRAS gene mutations. Some people with solid tumors of the colon or rectum (colorectal cancer), will be given ASP5834 with panitumumab. Panitumumab is a treatment for colorectal cancer. In this study, the researchers will learn how ASP5834 is processed by and acts upon the body. This information will help find a suitable dose of ASP5834 and check for any potential medical problems from the treatment. The main aims of this study are to check the safety of ASP5834 given by itself or given with panitumumab, and how well it is tolerated; and to find a suitable dose of ASP5834 given by itself or given with panitumumab. People in this study will be adults with locally advanced, unresectable, or metastatic solid tumors with certain KRAS gene mutations. Locally advanced means the cancer has spread to nearby tissue. Unresectable means the cancer cannot be removed by surgery. Metastatic means the cancer has spread to other parts of the body. They either haven't responded to standard treatment or couldn't be given standard treatment. The key reasons people cannot take part are if they have specific uncontrollable cancers such as symptomatic or untreated cancers in nervous system, have specific heart conditions, swelling and irritation of lung tissues (pneumonitis or interstitial lung disease, also called ILD), infections, or have recently had a stroke or a bleed on the brain. In this study, ASP5834 is being given to humans for the first time. This is an open-label study. This means that people in this study and clinic staff will know that they will receive ASP5834 by itself or ASP5834 with panitumumab. This study will be in 2 parts: Part 1 is called
Conditions Studied
Interventions
- DRUG ASP5834
- DRUG panitumumab
Study Locations (12)
Other
- Site FR33001 - Villejuif
- Site ES34001 - Madrid
- Site ES34003 - Madrid
Georgia
- Winship Cancer Institute at Emory University - Atlanta
Michigan
- START Midwest - Grand Rapids
Missouri
- Washington University School of Medicine - St Louis
New Jersey
- Hackensack University Medical Center - Hackensack
New York
- Memorial Sloan Kettering Cancer Center - New York
Texas
- NEXT Oncology Dallas - Irving
Virginia
- NEXT Oncology Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 364 participants |
| Start Date | 2025-07-25 |
| Est. Completion | 2029-04-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07094204
The ClinicalTrials.gov registry entry for NCT07094204 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 364 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (45% lower). The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which ASP5834 is the first listed.
NCT07094204 reports 12 study locations spanning 10 distinct geographic areas - top geographies include Other, Georgia, Michigan.
Frequently Asked Questions
What is clinical trial NCT07094204 about?
NCT07094204 is a clinical study titled "A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors". Genes contain genetic code which tell the body which proteins to make. Many types of cancer are caused by changes, or mutations, in a gene called KRAS. Researchers are looking for ways to stop the actions of abnormal proteins made from the mutated KRAS gene. ASP5834 is being studied in people with ...
What is the current status of trial NCT07094204?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 364 participants. The study started on 2025-07-25. Estimated completion is 2029-04-30.
What conditions does trial NCT07094204 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Pancreatic Ductal Adenocarcinoma.
What interventions are being tested in trial NCT07094204?
The interventions under investigation include: ASP5834 (DRUG), panitumumab (DRUG).
Who is sponsoring clinical trial NCT07094204?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07094204 being conducted?
This trial has 12 study locations across Georgia, Michigan, Missouri, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.